BioSante Pharmaceuticals to Present at 2006 BIO InvestorForum

  
    
  
  
    
      BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that Stephen 
      M. Simes, the Company’s president and chief 
      executive officer, will present a corporate and clinical overview of the 
      Company at the Biotechnology Industry Organization’s 
      BIO InvestorForum, taking place at the Palace Hotel in San Francisco, on 
      October 18-19, 2006.
    
    
      Mr. Simes’ presentation is scheduled for 
      October 18, 2006 at 4:20 p.m. PST. A live audio webcast of BioSante’s 
      presentation may be accessed at http://www.biosantepharma.com/investors/events.html 
      and a replay will be available at the same link for 90 days.
    
    
      About BioSante Pharmaceuticals, Inc.
    
    
      BioSante is developing a pipeline of hormone therapy products to treat 
      both men and women. These hormone therapy products are gel formulations 
      for transdermal administration that deliver bioidentical estradiol and 
      testosterone. BioSante's lead products include Bio-E-Gel® 
      (transdermal estradiol gel) for the treatment of women with menopausal 
      symptoms, and LibiGel® (transdermal 
      testosterone gel) for the treatment of female sexual dysfunction (FSD). 
      A Bio-E-Gel new drug application (NDA) was submitted to the FDA in the 
      first quarter 2006. The current market in the U.S. for estrogen and 
      testosterone products is approximately $2.5 billion. The transdermal gel 
      formulations used in the women's gel products are licensed by BioSante 
      from Antares Pharma Inc. The company also is developing its calcium 
      phosphate nanotechnology (CaP) for novel vaccines, including avian flu 
      and biodefense vaccines for toxins such as anthrax and ricin, and drug 
      delivery systems. Additional information is available online at: www.biosantepharma.com.
    
  
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that
Stephen M. Simes, the Company's president and chief executive officer,
will present a corporate and clinical overview of the Company at the
Biotechnology Industry Organization's BIO InvestorForum, taking place
at the Palace Hotel in San Francisco, on October 18-19, 2006.

   Mr. Simes' presentation is scheduled for October 18, 2006 at 4:20
p.m. PST. A live audio webcast of BioSante's presentation may be
accessed at http://www.biosantepharma.com/investors/events.html and a
replay will be available at the same link for 90 days.

   About BioSante Pharmaceuticals, Inc.

   BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(R) (transdermal estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(R) (transdermal testosterone
gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel
new drug application (NDA) was submitted to the FDA in the first
quarter 2006. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The transdermal
gel formulations used in the women's gel products are licensed by
BioSante from Antares Pharma Inc. The company also is developing its
calcium phosphate nanotechnology (CaP) for novel vaccines, including
avian flu and biodefense vaccines for toxins such as anthrax and
ricin, and drug delivery systems. Additional information is available
online at: www.biosantepharma.com.